相似文献
1
Huntington’s Disease Clinical Trials Corner: February 2018.亨廷顿舞蹈症临床试验角：2018年2月
J Huntingtons Dis. 2018;7(1):89-98. doi: 10.3233/JHD-189001.
2
Huntington's Disease Clinical Trials Corner: April 2020.亨廷顿舞蹈病临床试验角：2020 年 4 月。
J Huntingtons Dis. 2020;9(2):185-197. doi: 10.3233/JHD-200002.
3
Huntington's Disease Clinical Trials Corner: April 2022.亨廷顿病临床试验角：2022 年 4 月。
J Huntingtons Dis. 2022;11(2):105-118. doi: 10.3233/JHD-229002.
4
Clinical Trials Corner: September 2017.临床试验角：2017年9月
J Huntingtons Dis. 2017;6(3):255-263. doi: 10.3233/JHD-170262.
5
Huntington's Disease Clinical Trials Corner: January 2019.亨廷顿舞蹈症临床试验聚焦：2019年1月
J Huntingtons Dis. 2019;8(1):115-125. doi: 10.3233/JHD-190001.
6
Deutetrabenazine for the treatment of Huntington's chorea.曲美他嗪治疗亨廷顿舞蹈病。
Expert Rev Neurother. 2018 Aug;18(8):625-631. doi: 10.1080/14737175.2018.1500178. Epub 2018 Jul 17.
7
Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.曲美他嗪治疗迟发性运动障碍和亨廷顿舞蹈病相关的舞蹈症：临床试验数据综述。
Expert Opin Pharmacother. 2019 Dec;20(18):2209-2221. doi: 10.1080/14656566.2019.1674281. Epub 2019 Oct 15.
8
Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.曲美他嗪：治疗亨廷顿舞蹈病相关舞蹈症的药物评价。
Drugs. 2017 Nov;77(17):1857-1864. doi: 10.1007/s40265-017-0831-0.
9
Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.氘代丁苯那嗪综述：一种治疗亨廷顿舞蹈症相关舞蹈症的新疗法。
Drug Des Devel Ther. 2018 Feb 15;12:313-319. doi: 10.2147/DDDT.S138828. eCollection 2018.
10
Huntington's Disease Clinical Trials Update: September 2024.亨廷顿舞蹈症临床试验更新：2024年9月
J Huntingtons Dis. 2024 Nov;13(4):409-418. doi: 10.1177/18796397241293955. Epub 2024 Oct 26.
引用本文的文献
1
Huntington's disease clinical trials update: March 2025.亨廷顿舞蹈症临床试验更新：2025年3月
J Huntingtons Dis. 2025 May;14(2):191-206. doi: 10.1177/18796397251337000. Epub 2025 Apr 30.
2
Huntington's Disease Clinical Trials Corner: March 2024.亨廷顿病临床试验角：2024 年 3 月。
J Huntingtons Dis. 2024;13(1):1-14. doi: 10.3233/JHD-240017.
3
Advances in Nucleic Acid Research: Exploring the Potential of Oligonucleotides for Therapeutic Applications and Biological Studies.核酸研究进展：探索寡核苷酸在治疗应用和生物研究中的潜力。
Int J Mol Sci. 2023 Dec 21;25(1):146. doi: 10.3390/ijms25010146.
4
Metabolomics: An Emerging "Omics" Platform for Systems Biology and Its Implications for Huntington Disease Research.代谢组学：一种用于系统生物学的新兴“组学”平台及其对亨廷顿病研究的意义
Metabolites. 2023 Dec 18;13(12):1203. doi: 10.3390/metabo13121203.
5
From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology.从识别到治疗：神经退行性疾病病理学中生物标志物的意义。
Int J Mol Sci. 2023 Nov 9;24(22):16119. doi: 10.3390/ijms242216119.
6
Huntington's Disease Clinical Trials Corner: August 2023.亨廷顿病临床试验角：2023 年 8 月。
J Huntingtons Dis. 2023;12(2):169-185. doi: 10.3233/JHD-239001.
7
Current and Possible Future Therapeutic Options for Huntington's Disease.亨廷顿舞蹈症当前及未来可能的治疗选择
J Cent Nerv Syst Dis. 2022 May 21;14:11795735221092517. doi: 10.1177/11795735221092517. eCollection 2022.
8
Gene targeting techniques for Huntington's disease.亨廷顿病的基因靶向技术。
Ageing Res Rev. 2021 Sep;70:101385. doi: 10.1016/j.arr.2021.101385. Epub 2021 Jun 5.
9
Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington's Disease.验证自动分割工具在评估亨廷顿舞蹈病尾状核萎缩中的应用
Front Neurol. 2021 Apr 14;12:616272. doi: 10.3389/fneur.2021.616272. eCollection 2021.
10
Genetic epidemiological characteristics of a Hungarian subpopulation of patients with Huntington's disease.匈牙利亨廷顿病患者亚群的遗传流行病学特征。
BMC Neurol. 2021 Feb 18;21(1):79. doi: 10.1186/s12883-021-02089-9.
本文引用的文献
1
Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease".元研究指标很重要：关于文章《氘代丁苯那嗪与丁苯那嗪治疗亨廷顿病的间接耐受性比较》的信函
J Clin Mov Disord. 2017 Nov 22;4:19. doi: 10.1186/s40734-017-0067-x. eCollection 2017.
2
Clinical Trials Corner: September 2017.临床试验角：2017年9月
J Huntingtons Dis. 2017;6(3):255-263. doi: 10.3233/JHD-170262.
3
Therapies targeting DNA and RNA in Huntington's disease.针对亨廷顿舞蹈症中DNA和RNA的疗法。
Lancet Neurol. 2017 Oct;16(10):837-847. doi: 10.1016/S1474-4422(17)30280-6. Epub 2017 Sep 12.
4
Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?用于治疗亨廷顿舞蹈症的丁苯那嗪与氘代丁苯那嗪：双胞胎还是远房表亲？
Mov Disord Clin Pract. 2017 Jul-Aug;4(4):582-585. doi: 10.1002/mdc3.12483. Epub 2017 Mar 29.
5
Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.控制硫代磷酸酯立体化学可显著提高反义寡核苷酸的疗效。
Nat Biotechnol. 2017 Sep;35(9):845-851. doi: 10.1038/nbt.3948. Epub 2017 Aug 21.
6
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.从丁苯那嗪转换为氘代丁苯那嗪治疗舞蹈症的安全性
JAMA Neurol. 2017 Aug 1;74(8):977-982. doi: 10.1001/jamaneurol.2017.1352.
7
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.氘代丁苯那嗪与丁苯那嗪治疗亨廷顿病的间接耐受性比较
J Clin Mov Disord. 2017 Mar 1;4:3. doi: 10.1186/s40734-017-0051-5. eCollection 2017.
8
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.地西他滨治疗亨廷顿舞蹈病患者舞蹈症的效果：一项随机临床试验。
JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.
9
The Biology of Huntingtin.亨廷顿蛋白的生物学。
Neuron. 2016 Mar 2;89(5):910-26. doi: 10.1016/j.neuron.2016.02.003.
10
Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.亨廷顿单倍型为欧洲血统的亨廷顿病患者提供了用于等位基因特异性沉默的优先靶向面板。
Mol Ther. 2015 Nov;23(11):1759-1771. doi: 10.1038/mt.2015.128. Epub 2015 Jul 23.
Zotero 插件